97 related articles for article (PubMed ID: 8231461)
1. Measurements of serum ACE activity in vitro after administration of enalapril in man cannot reflect inhibition of the enzyme in vivo.
Weisser K; Schloos J
Methods Find Exp Clin Pharmacol; 1993; 15(6):413-8. PubMed ID: 8231461
[TBL] [Abstract][Full Text] [Related]
2. Relationship of antihypertensive effect of enalapril to serum MK-422 levels and angiotensin converting enzyme inhibition.
Johnston CI; Jackson B; McGrath B; Matthews G; Arnolda L
J Hypertens Suppl; 1983 Oct; 1(1):71-5. PubMed ID: 6100611
[TBL] [Abstract][Full Text] [Related]
3. Effect of captopril and enalapril medication on the serum ACE test for sarcoidosis.
Lieberman J; Zakria F
Sarcoidosis; 1989 Sep; 6(2):118-23. PubMed ID: 2557660
[TBL] [Abstract][Full Text] [Related]
4. The role of enzyme and substrate concentration in the evaluation of serum angiotensin converting enzyme (ACE) inhibition by enalaprilat in vitro.
Weisser K; Schloos J
Biochem Pharmacol; 1991 Oct; 42(9):1729-37. PubMed ID: 1656995
[TBL] [Abstract][Full Text] [Related]
5. Enalapril pharmacokinetics and ACE inhibition, following single and chronic oral dosing.
Edeki T; Johnston A; Li Kam Wa E; Turner P
Int J Clin Pharmacol Ther; 1994 Mar; 32(3):142-6. PubMed ID: 8205376
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of angiotensin converting enzyme from sheep tissues by captopril, lisinopril and enalapril.
Udupa EG; Rao NM
Indian J Biochem Biophys; 1997 Dec; 34(6):524-8. PubMed ID: 9594434
[TBL] [Abstract][Full Text] [Related]
7. Estimation of rate constants for reactions of pulmonary microvascular angiotensin converting enzyme with an inhibitor and a substrate in vivo.
Ryan JW; Valido FA; Sequeira MJ; Chung AY; Berryer P; Chen XL; Catravas JD
J Pharmacol Exp Ther; 1994 Jul; 270(1):260-8. PubMed ID: 8035324
[TBL] [Abstract][Full Text] [Related]
8. High serum enalaprilat in chronic renal failure.
Elung-Jensen T; Heisterberg J; Kamper AL; Sonne J; Strandgaard S; Larsen NE
J Renin Angiotensin Aldosterone Syst; 2001 Dec; 2(4):240-5. PubMed ID: 11881130
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics and population pharmacokinetics of enalapril and lisinopril.
Ajayi AA; Campbell BC; Kelman AW; Howie C; Meredith PA; Reid JL
Int J Clin Pharmacol Res; 1985; 5(6):419-27. PubMed ID: 3005181
[TBL] [Abstract][Full Text] [Related]
10. Procyanidin structure defines the extent and specificity of angiotensin I converting enzyme inhibition.
Ottaviani JI; Actis-Goretta L; Villordo JJ; Fraga CG
Biochimie; 2006; 88(3-4):359-65. PubMed ID: 16330143
[TBL] [Abstract][Full Text] [Related]
11. Correlation between ACE activity and mean blood pressure in Iranian normotensive subjects after oral administration of a single dose of enalapril.
Ziai SA; Seyedhosseini D; Taiebi L; Salekmoghadam E; Mahmoudian M
Acta Physiol Hung; 2000; 87(2):153-9. PubMed ID: 11205963
[TBL] [Abstract][Full Text] [Related]
12. Should the use of short acting angiotensin-converting enzyme inhibitors be abandoned?
Erman A; Boner G; van Dijk DJ
J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):365-8. PubMed ID: 11967825
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme inhibitors: measurement of relative inhibitory potency and serum drug levels by radioinhibitor binding displacement assay.
Jackson B; Cubela R; Johnston CI
J Cardiovasc Pharmacol; 1987 Jun; 9(6):699-704. PubMed ID: 2442537
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic comparative study of zofenopril and enalapril in healthy volunteers.
Marzo A; Dal Bo L; Mazzucchelli P; Monti NC; Crivelli F; Ismaili S; Giusti A; Uhr MR
Arzneimittelforschung; 2002; 52(4):233-42. PubMed ID: 12040965
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin I-converting enzyme inhibition but not angiotensin II suppression alters angiotensin I-converting enzyme gene expression in vessels and epithelia.
Costerousse O; Allegrini J; Clozel JP; Ménard J; Alhenc-Gelas F
J Pharmacol Exp Ther; 1998 Mar; 284(3):1180-7. PubMed ID: 9495881
[TBL] [Abstract][Full Text] [Related]
16. Compared properties of trandolapril, enalapril, and their diacid metabolites.
Chevillard C; Jouquey S; Bree F; Mathieu MN; Stepniewski JP; Tillement JP; Hamon G; Corvol P
J Cardiovasc Pharmacol; 1994; 23 Suppl 4():S11-5. PubMed ID: 7527095
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the pharmacokinetic and pharmacodynamic properties of the angiotensin-converting enzyme inhibitor, enalapril, in horses.
Gardner SY; Atkins CE; Sams RA; Schwabenton AB; Papich MG
J Vet Intern Med; 2004; 18(2):231-7. PubMed ID: 15058776
[TBL] [Abstract][Full Text] [Related]
18. Dissociation between ACE activity and autonomic response to ACE inhibition in patients with heart failure.
Binkley PF; Nunziata E; Haas GJ; Starling RC; Leier CV; Cody RJ
Am Heart J; 2000 Jul; 140(1):34-42. PubMed ID: 10874261
[TBL] [Abstract][Full Text] [Related]
19. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
[TBL] [Abstract][Full Text] [Related]
20. The pharmacological mechanism of angiotensin-converting enzyme inhibition by green tea, Rooibos and enalaprilat - a study on enzyme kinetics.
Persson IA
Phytother Res; 2012 Apr; 26(4):517-21. PubMed ID: 22095883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
